Variable effects of chronic subcutaneous administration of rotenone on striatal histology
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
When infused in rats, rotenone, a mitochondrial complex I inhibitor, induces alterations that resemble the histological changes of Parkinson's disease, particularly degeneration of the nigrostriatal dopaminergic system. However, the specificity of rotenone effects has been challenged recently. We have re‐examined the alterations caused by rotenone in the substantia nigra and the striatum of rats after infusion of rotenone (2 mg/kg per day s.c.) for 21 days. Three patterns of striatal tyrosine‐hydroxylase immunoreactivity (TH‐IR) were observed: 46% of animals showed no reduction, and 46% of animals showed diffuse reduction in TH‐IR, whereas one animal presented a focal loss of TH‐IR in the striatum. Confocal microscopy analysis showed that the vesicular monoamine transporter (VMAT2) was decreased in parallel with TH‐IR, strongly suggesting a loss of striatal DA nerve terminals in animals with diffuse or central TH‐IR loss. However, no significant loss of TH‐IR neurons was observed in the substantia nigra. Analysis of NeuN and DARPP‐32 immunoreactivity, and Nissl staining, in the striatum showed no striatal neuronal loss in animals with either preserved TH‐IR or diffuse TH‐IR reduction. However, in the animal with focal TH‐IR loss, severe neuronal loss was evident in the center and the periphery of the striatum, together with microglial activation detected by OX‐6 and OX‐42 staining. Thus, in most cases, chronic subcutaneous infusion of low doses of rotenone does not induce significant striatal neuronal loss, despite TH‐IR and VMAT‐IR reduction in a subset of animals, supporting the use of rotenone as a model of Parkinson's disease under carefully controlled experimental conditions. J. Comp. Neurol. 478:418–426, 2004. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Pathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693 · cited 1×
“…complex I; striatum; substantia nigra; tyrosine hydroxylase; vesicular monoamine transporter; microglia Parkinson’s disease (PD) is characterized by a selective and progressive neurodegeneration of the nigrostriatal dopaminergic pathway without loss of striatal neurons (Braak and Braak, 2000).”
BackgroundΔΨ m ‐Dependent and ‐independent production of reactive oxygen species by rat brain mitochondria
Votyakova, T. V., & Reynolds, I. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00548.x · Cited by 601
Control of glial immune function by neurons
Neumann, H. (2001) · Glia · doi:10.1002/glia.1108 · Cited by 319
Cited by
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S. R., & Chesselet, M.-F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 913
Self-citationToxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Cicchetti, F., Drouin-Ouellet, J., & Gross, R. E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.005 · Cited by 311
Testa, C. M., Sherer, T. B., & Greenamyre, J. T. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.11.007 · Cited by 299
Novel Insights into NeuN: from Neuronal Marker to Splicing Regulator
Duan, W., Zhang, Y.-P., Hou, Z., Huang, C., Zhu, H., Zhang, C.-Q., & Yin, Q. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9122-5 · Cited by 294
Inden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04440.x · Cited by 260
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Metadata
- Authors
- Zhu, C., Vourc'h, P., Fernagut, P., Fleming, S. M., Lacan, S., Dicarlo, C. D., Seaman, R. L., & Chesselet, M.
- Venue
- Journal of Comparative Neurology
- Publisher
- Wiley
- Published
- 2004-09-21
- Volume
- 478
- Issue
- 4
- Pages
- 418-426
- ISSN
- 0021-9967 (ISSN-L)
- 1096-9861
- OpenAlex
- W2000329625
- Cited by
- 101
- References
- 4
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.